Toro, DBV Technologies, Udemy, ABM Industries, and Other Major Stocks Rising on Wednesday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy KOD?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining over 150 points, while several companies, including Toro Co, reported better-than-expected quarterly earnings, leading to significant stock price increases.
Notable Stock Gains: Toro Co's shares rose 7% after reporting earnings of 91 cents per share, while DBV Technologies saw a 35.5% increase following positive trial results. Other companies like Udemy and Kodiak Sciences also experienced substantial gains.
Sector Highlights: Cannabis-related stocks surged after reports of potential reclassification of marijuana, with Canopy Growth Corp gaining 16.2%. Lithium-related stocks also rose following the cancellation of mining permits in Yichun.
Company Announcements and Upgrades: Several companies, including Recursion Pharmaceuticals and Two Harbors Investment Corp, saw stock price increases due to upgrades and acquisition announcements, reflecting positive investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KOD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 26.800
Low
14.00
Averages
27.86
High
50.00
Current: 26.800
Low
14.00
Averages
27.86
High
50.00
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baker Bros. Advisors Increases Stake in Kodiak Sciences
- Share Increase: Baker Bros. Advisors LP disclosed a purchase of 2,608,696 shares of Kodiak Sciences during Q4 2025, representing an estimated $53.42 million investment, indicating strong confidence in the company's future prospects.
- Value Growth: Following this acquisition, the value of Kodiak Sciences' holdings reached $273.57 million at quarter-end, reflecting significant stock price appreciation and increased market recognition.
- Outstanding Market Performance: As of February 23, 2026, Kodiak's shares were priced at $25.91, marking a staggering 480% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing its robust performance in the biopharmaceutical sector.
- Ongoing R&D Investment: The company reported R&D expenditures of $50.5 million in Q3, with a quarterly net loss of $61.5 million; however, its potential in treating retinal diseases continues to attract investor interest due to the substantial market opportunities available.
See More
Baker Bros. Advisors Increases Stake in Kodiak Sciences
- Stake Increase: Baker Bros. Advisors increased its stake in Kodiak Sciences by 2,608,696 shares during Q4 2025, with an estimated trade value of $53.42 million, indicating ongoing confidence in the company's prospects.
- Value Growth: The value of Kodiak Sciences' holdings rose by $273.57 million at quarter-end, reflecting both the addition of shares and stock price appreciation, which underscores market recognition of its future potential.
- R&D Investment: Kodiak's R&D spending reached $50.5 million in Q3, despite a quarterly net loss of $61.5 million, while cash reserves stood at $72 million as of September 30, demonstrating the company's commitment to innovation.
- Market Opportunity: Kodiak aims to compete in the approximately $15 billion anti-VEGF market, and if Phase 3 data validate its ABC platform, it could secure a significant position in the retinal vascular disease sector.
See More
Braidwell Acquires Significant Stake in Kodiak Sciences
- Share Acquisition Details: Braidwell LP disclosed a new position in Kodiak Sciences by acquiring 2,072,788 shares valued at approximately $57.96 million during Q4 2025, indicating strong confidence in the company's prospects.
- Portfolio Allocation Insight: This acquisition represents 1.85% of Braidwell's 13F reportable AUM, highlighting Kodiak's significance within the portfolio while maintaining a cautious investment approach.
- Company Performance Metrics: As of February 17, 2026, Kodiak Sciences' stock price reached $22.66, reflecting a remarkable 340% increase over the past year, significantly outperforming the S&P 500, which underscores market recognition of its growth potential.
- R&D and Market Outlook: Focused on therapeutics for retinal diseases, Kodiak is advancing three late-stage clinical trials with pivotal data expected in 2026, targeting a global anti-VEGF market estimated at $15 billion, which has drawn investor interest due to its substantial commercial potential.
See More
Kodiak Sciences to Present APEX Study Results at Angiogenesis Meeting
- Clinical Study Results: Kodiak Sciences will present the first end-of-study results from the APEX study at the virtual Angiogenesis meeting on February 7, 2026, showcasing KSI-101's efficacy in patients with macular edema secondary to inflammation, further supporting its clinical safety and efficacy profile.
- Research Progress: The APEX study demonstrated that KSI-101 provides significant anatomical and visual improvements in patients with inflammation-related macular edema, indicating its potential to become a unifying treatment option, thereby enhancing the company's competitive position in the biotherapeutics market.
- Follow-up Research Plans: Currently, the PEAK and PINNACLE Phase 3 studies are actively enrolling patients, with KSI-101 being tested at two dose levels (5mg and 10mg) against a sham, which is expected to provide new treatment options for the market.
- Market Potential: KSI-101 targets a market segment for macular edema diseases that currently lacks available biologic therapies, and Kodiak Sciences aims to penetrate this new market segment, which is anticipated to positively impact the company's future revenue growth.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Kodiak Sciences to Present at J.P. Morgan Conference on January 12, 2026
- Conference Presentation: Kodiak Sciences will present at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing its latest advancements in retinal disease treatments, which is expected to attract investor and industry attention.
- Clinical Research Progress: The company is advancing three late-stage clinical programs, with Tarcocimab and KSI-501 targeting the $15 billion anti-VEGF market, and topline data readouts expected in Q1 and Q3 2026, potentially impacting market positioning.
- New Drug Development: KSI-101, a bispecific protein, is undergoing two BLA clinical trials for Macular Edema Secondary to Inflammation, with data expected in Q4 2026 and Q2 2027, which could further enrich the product pipeline if successful.
- Market Potential: Kodiak Sciences is committed to developing transformative therapeutics aimed at addressing the leading causes of blindness globally, and with the release of clinical data, the company is poised to capture a larger market share in the biotechnology sector.
See More
Baker Bros. Advisors Increases Stake in Kodiak Sciences
- Share Increase: Baker Bros. Advisors LP disclosed a purchase of 2,608,696 shares of Kodiak Sciences during Q4 2025, representing an estimated $53.42 million investment, indicating strong confidence in the company's future prospects.
- Value Growth: Following this acquisition, the value of Kodiak Sciences' holdings reached $273.57 million at quarter-end, reflecting significant stock price appreciation and increased market recognition.
- Outstanding Market Performance: As of February 23, 2026, Kodiak's shares were priced at $25.91, marking a staggering 480% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing its robust performance in the biopharmaceutical sector.
- Ongoing R&D Investment: The company reported R&D expenditures of $50.5 million in Q3, with a quarterly net loss of $61.5 million; however, its potential in treating retinal diseases continues to attract investor interest due to the substantial market opportunities available.
See More
Baker Bros. Advisors Increases Stake in Kodiak Sciences
- Stake Increase: Baker Bros. Advisors increased its stake in Kodiak Sciences by 2,608,696 shares during Q4 2025, with an estimated trade value of $53.42 million, indicating ongoing confidence in the company's prospects.
- Value Growth: The value of Kodiak Sciences' holdings rose by $273.57 million at quarter-end, reflecting both the addition of shares and stock price appreciation, which underscores market recognition of its future potential.
- R&D Investment: Kodiak's R&D spending reached $50.5 million in Q3, despite a quarterly net loss of $61.5 million, while cash reserves stood at $72 million as of September 30, demonstrating the company's commitment to innovation.
- Market Opportunity: Kodiak aims to compete in the approximately $15 billion anti-VEGF market, and if Phase 3 data validate its ABC platform, it could secure a significant position in the retinal vascular disease sector.
See More
Braidwell Acquires Significant Stake in Kodiak Sciences
- Share Acquisition Details: Braidwell LP disclosed a new position in Kodiak Sciences by acquiring 2,072,788 shares valued at approximately $57.96 million during Q4 2025, indicating strong confidence in the company's prospects.
- Portfolio Allocation Insight: This acquisition represents 1.85% of Braidwell's 13F reportable AUM, highlighting Kodiak's significance within the portfolio while maintaining a cautious investment approach.
- Company Performance Metrics: As of February 17, 2026, Kodiak Sciences' stock price reached $22.66, reflecting a remarkable 340% increase over the past year, significantly outperforming the S&P 500, which underscores market recognition of its growth potential.
- R&D and Market Outlook: Focused on therapeutics for retinal diseases, Kodiak is advancing three late-stage clinical trials with pivotal data expected in 2026, targeting a global anti-VEGF market estimated at $15 billion, which has drawn investor interest due to its substantial commercial potential.
See More
Kodiak Sciences to Present APEX Study Results at Angiogenesis Meeting
- Clinical Study Results: Kodiak Sciences will present the first end-of-study results from the APEX study at the virtual Angiogenesis meeting on February 7, 2026, showcasing KSI-101's efficacy in patients with macular edema secondary to inflammation, further supporting its clinical safety and efficacy profile.
- Research Progress: The APEX study demonstrated that KSI-101 provides significant anatomical and visual improvements in patients with inflammation-related macular edema, indicating its potential to become a unifying treatment option, thereby enhancing the company's competitive position in the biotherapeutics market.
- Follow-up Research Plans: Currently, the PEAK and PINNACLE Phase 3 studies are actively enrolling patients, with KSI-101 being tested at two dose levels (5mg and 10mg) against a sham, which is expected to provide new treatment options for the market.
- Market Potential: KSI-101 targets a market segment for macular edema diseases that currently lacks available biologic therapies, and Kodiak Sciences aims to penetrate this new market segment, which is anticipated to positively impact the company's future revenue growth.
See More
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
See More
Kodiak Sciences to Present at J.P. Morgan Conference on January 12, 2026
- Conference Presentation: Kodiak Sciences will present at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing its latest advancements in retinal disease treatments, which is expected to attract investor and industry attention.
- Clinical Research Progress: The company is advancing three late-stage clinical programs, with Tarcocimab and KSI-501 targeting the $15 billion anti-VEGF market, and topline data readouts expected in Q1 and Q3 2026, potentially impacting market positioning.
- New Drug Development: KSI-101, a bispecific protein, is undergoing two BLA clinical trials for Macular Edema Secondary to Inflammation, with data expected in Q4 2026 and Q2 2027, which could further enrich the product pipeline if successful.
- Market Potential: Kodiak Sciences is committed to developing transformative therapeutics aimed at addressing the leading causes of blindness globally, and with the release of clinical data, the company is poised to capture a larger market share in the biotechnology sector.
See More
